Cargando…

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)

Inhibition of more than one cancer‐related pathway by multi‐target agents is an emerging approach in modern anticancer drug discovery. Here, based on the well‐established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series of alkylating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinatra, Laura, Bandolik, Jan J., Roatsch, Martin, Sönnichsen, Melf, Schoeder, Clara T., Hamacher, Alexandra, Schöler, Andrea, Borkhardt, Arndt, Meiler, Jens, Bhatia, Sanil, Kassack, Matthias U., Hansen, Finn K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756583/ https://www.ncbi.nlm.nih.gov/pubmed/32780485 http://dx.doi.org/10.1002/anie.202006725

Ejemplares similares

Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity
por: Pflieger, Marc, et al.
Publicado: (2021)

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
por: Bandolik, Jan J., et al.
Publicado: (2019)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
por: von Bredow, Lukas, et al.
Publicado: (2022)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Synthesis and HDAC inhibitory activity of pyrimidine-based hydroxamic acids
por: Jakubkiene, Virginija, et al.
Publicado: (2022)

Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
por: Alsawalha, Murad, et al.
Publicado: (2019)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
por: Goracci, Laura, et al.
Publicado: (2016)

Correction to: Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)
por: Baker, India M., et al.
Publicado: (2022)

Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile
por: Selg, Christoph, et al.
Publicado: (2021)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
por: Chopra, Vanita, et al.
Publicado: (2016)

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation
por: Márquez-Cantudo, Laura, et al.
Publicado: (2021)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
por: Zagni, Chiara, et al.
Publicado: (2019)

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies
por: García, Santiago, et al.
Publicado: (2020)

Hydroxamic Acid-Modified Peptide Library Provides Insights into the Molecular Basis for the Substrate Selectivity of HDAC Corepressor Complexes
por: Archibald, Lewis J., et al.
Publicado: (2022)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
por: Yang, Feifei, et al.
Publicado: (2019)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
por: Darwish, Salma, et al.
Publicado: (2022)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
por: Schrenk, Christian, et al.
Publicado: (2023)

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
por: Schmitt, Florian, et al.
Publicado: (2019)

HDAC3 and HDAC8 are required for cilia assembly and elongation
por: Park, Seon-ah, et al.
Publicado: (2019)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells
por: Rivera-Del Valle, Nilsa, et al.
Publicado: (2010)

Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer
por: Abdel-Atty, Mona M., et al.
Publicado: (2021)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019)

Development of the first geldanamycin-based HSP90 degraders
por: Wurnig, Silas, et al.
Publicado: (2023)

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
por: Smalley, Joshua P., et al.
Publicado: (2022)

The HDAC interaction network
por: Livyatan, Ilana, et al.
Publicado: (2013)

Suberoylanilide hydroxamic acid suppresses axonal damage and neurological dysfunction after subarachnoid hemorrhage via the HDAC1/HSP70/TDP-43 axis
por: Luo, Kui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hl9qg0l8o86e5j8vluhm61m1al